Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert A Figlin

Showing results (1-10 of 200) with videos related to

Pageof 20
Sort By:
Clinical Advances in Hematology & Oncology : H&O|August 2, 2018
Highlights in kidney cancer from the American Society of Clinical Oncology Genitourinary Cancers SymposiumRobert A Figlin
Clinical Advances in Hematology & Oncology : H&O|January 11, 2008
Temsirolimus for advanced renal cell carcinomaRobert A Figlin
Clinical Advances in Hematology & Oncology : H&O|March 7, 2007
Newly approved therapies for RCC and their effect on the standard of careRobert A Figlin
Immunotherapy|December 21, 2013
A novel personalized vaccine approach in combination with targeted therapy in advanced renal cell carcinomaRobert A Figlin
Expert Opinion on Biological Therapy|July 1, 2015
Personalized immunotherapy ( AGS-003 ) when combined with sunitinib for the treatment of metastatic renal cell carcinomaRobert A Figlin
Seminars in Oncology|October 19, 2006
Renal cell carcinoma: the translation of biology to clinical applicationRobert A Figlin
Nature Clinical Practice. Oncology|July 9, 2008
Mechanisms of Disease: survival benefit of temsirolimus validates a role for mTOR in the management of advanced RCCRobert A Figlin
Clinical Advances in Hematology & Oncology : H&O|December 31, 2009
Anti-angiogenic therapy in renal cell carcinoma: Alone, in combination, or sequentiallyRobert A Figlin
Cancer Journal (Sudbury, Mass.)|July 23, 2013
From the guest editor: renal cell carcinoma: the next decade of developmentRobert A Figlin
Clinical Advances in Hematology & Oncology : H&O|May 10, 2018
Highlights in renal cell carcinoma from the Sixteenth International Kidney Cancer Symposium: commentaryRobert A Figlin
Pageof 20

Showing results (1-10 of 200) with videos related to

Sort By:
Pageof 20
Clinical Advances in Hematology & Oncology : H&O|August 2, 2018
Highlights in kidney cancer from the American Society of Clinical Oncology Genitourinary Cancers SymposiumRobert A Figlin
Clinical Advances in Hematology & Oncology : H&O|January 11, 2008
Temsirolimus for advanced renal cell carcinomaRobert A Figlin
Clinical Advances in Hematology & Oncology : H&O|March 7, 2007
Newly approved therapies for RCC and their effect on the standard of careRobert A Figlin
Immunotherapy|December 21, 2013
A novel personalized vaccine approach in combination with targeted therapy in advanced renal cell carcinomaRobert A Figlin
Expert Opinion on Biological Therapy|July 1, 2015
Personalized immunotherapy ( AGS-003 ) when combined with sunitinib for the treatment of metastatic renal cell carcinomaRobert A Figlin
Seminars in Oncology|October 19, 2006
Renal cell carcinoma: the translation of biology to clinical applicationRobert A Figlin
Nature Clinical Practice. Oncology|July 9, 2008
Mechanisms of Disease: survival benefit of temsirolimus validates a role for mTOR in the management of advanced RCCRobert A Figlin
Clinical Advances in Hematology & Oncology : H&O|December 31, 2009
Anti-angiogenic therapy in renal cell carcinoma: Alone, in combination, or sequentiallyRobert A Figlin
Cancer Journal (Sudbury, Mass.)|July 23, 2013
From the guest editor: renal cell carcinoma: the next decade of developmentRobert A Figlin
Clinical Advances in Hematology & Oncology : H&O|May 10, 2018
Highlights in renal cell carcinoma from the Sixteenth International Kidney Cancer Symposium: commentaryRobert A Figlin
Pageof 20